Answers are grounded in this paper and cite their sources.
Studies of blood serotonin concentrations in autism and mental retardation suggest a possible dysfunction of serotonin in substantial proportions of patients. Clomipramine (CMI) and the selective serotonin reuptake inhibitors (SSRIs) are documented as effective in managing obsessive-compulsive disorder (OCD) symptoms as well as depression. Some workers construe perseverative behavior as a variant of OCD and certain forms of self-injury as a symptom of underlying depression or OCD, leading to extensive use of these agents in autism and mental retardation. CMI and the SSRIs share common features in terms of pharmacodynamics, pharmacokinetics, and side effects, but they also have important differences. To date there have been at least 14 reports of CMI use and at least 33 reports of SSRI use to manage perseverative behavior in patients with developmental disabilities. The large majority of these reports suggest beneficial effects on perseverative behavior, but most are case reports or uncontrolled studies. The existing literature suggests that practitioners may use these serotonergic agents on an experimental basis to manage repetitive behaviors in this population. However, properly controlled studies are needed to (a) assess clinical efficacy more objectively; (b) evaluate patient characteristics (age, diagnosis, type of perseverative behavior) in relation to response; (c) compare differential response to these agents; (d) examine dose–response relationships; (e) assess any moderating effect of IQ; and (f) determine whether baseline serotonin profiles predict treatment outcome. MRDD Research Reviews 1999;5:279–289.
No takes yet. Share an insight, caveat, or question.
Aman et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: